Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant, dose-dependent weight loss and HbA1c reduction in overweight and obese adults with type 2 diabetes, with efficacy increasing at doses of 5mg, 10mg, and 15mg administered once weekly.
If you have type 2 diabetes and are overweight or obese, Tirzepatide is a highly effective, once-weekly injection that helps you lose significant weight and lower your blood sugar. The higher the dose (up to 15mg), the more weight you tend to lose. While you might experience side effects like nausea or diarrhea, especially at higher doses, most people get used to it. It is more effective than many existing obesity medications.
The pooled findings showed that Tirzepatide vs control significantly reduced body weight (mean difference (MD): -7.38, 95% confidence interval (CI): -13.66 to -1.09, P=0.02). The results of subgroup analysis showed that the trend of weight loss is dose-dependent (5mg: MD: -6.87... 10 mg: MD: -9.62... 15mg: MD: -11.00...)
Why this rating
The claim is based on a systematic review and meta-analysis of 11 randomized controlled trials involving 11,710 participants, with high Jadad scores.
Source
Management of Overweight and Obese People with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review
Liya Fu et al. · Clinical Medicine Frontiers · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →